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ABSTRACT
Background
Pancreatic ductal adenocarcinoma (PDAC) carries an extremely poor prognosis, typically
presenting with metastasis at the time of diagnosis and exhibiting profound resistance to
existing therapies. The development of molecular markers and imaging probes for incipient
PDAC would enable earlier detection and guide the development of interventive therapies.
Here we sought to identify novel molecular markers and to test their potential as targeted
imaging agents.
Methods and Findings
Here, a phage display approach was used in a mouse model of PDAC to screen for peptides
that specifically bind to cell surface antigens on PDAC cells. These screens yielded a motif that
distinguishes PDAC cells from normal pancreatic duct cells in vitro, which, upon proteomics
analysis, identified plectin-1 as a novel biomarker of PDAC. To assess their utility for in vivo
imaging, the plectin-1 targeted peptides (PTP) were conjugated to magnetofluorescent
nanoparticles. In conjunction with intravital confocal microscopy and MRI, these nanoparticles
enabled detection of small PDAC and precursor lesions in engineered mouse models.
Conclusions
Our approach exploited a well-defined model of PDAC, enabling rapid identification and
validation of PTP. The developed specific imaging probe, along with the discovery of plectin-1
as a novel biomarker, may have clinical utility in the diagnosis and management of PDAC in
humans.
The Editors’ Summary of this article follows the references.
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Pancreatic ductal adenocarcinoma (PDAC) is the fourth
leading cause of cancer deaths in the United States and shows
a rapid clinical course, with a median survival of 6 mo and a
5-y survival rate of only 3% [1]. As chemotherapy and
radiotherapy have only modest beneﬁts, and surgery is only
possible in 20% of patients, early detection that allows
surgical resection offers the best hope for longer survival [2].
Indeed, the detection of PDAC or high-grade precursors in
high-risk patient groups (e.g., hereditary cancer syndromes,
chronic pancreatitis, and new-onset diabetes) represents a
critical unmet need in the cancer diagnostic portfolio [3,4].
Additionally, tools to distinguish PDAC from benign cystic
lesions frequently detected incidentally on cross-sectional
imaging would be clinically useful by diminishing the need
for invasive procedures. Currently, serum CA-19–9 is the
only clinically used biomarker; however, it lacks the
sensitivity needed to detect early-stage PDAC [5]. In addition,
cross-sectional abdominal imaging has proven to be unreli-
able to detect early-stage PDAC in high-risk patients [6].
Therefore, considerable ongoing efforts aimed at identifying
new PDAC detection biomarkers are currently being pursued
using a variety of approaches including serum proteomics,
expression proﬁling of tumor tissue, genetic analysis of
pancreatic ﬂuid, and methods using combinatorial chemistry
[5,7–10].
There is a substantial challenge in studying the early
molecular changes in PDAC because of the typical presenta-
tion of PDAC at advanced stage and the corresponding lack
of suitable tissue specimens. Therefore, we elected to exploit
a series of related genetically engineered mouse models of
PDAC that harbor the signature gene mutations of the human
disease, including Kras activation and deletion of the p53 or
Ink4a/Arf tumor suppressors [11,12]. The tumors in these
models exhibit the characteristic multistage histopathological
progression (from precursor pancreatic intraepithelial neo-
plasis [PanINs] [13] to metastatic cancer) that deﬁnes PDAC
in humans, providing tractable model systems for both
biological and preclinical studies [11]. From these mouse
models, we have been able to generate primary cell lines
derived from emerging PDAC. These early-stage cancer cell
lines, in conjunction with normal pancreatic ductal cells from
wild-type mice [14], could facilitate screening for biomarkers
and imaging agents using combinatorial chemistry-based
approaches.
Early work to develop better diagnostic and therapeutic
molecules has focused on the use of antibodies for tumor
recognition and drug delivery [15,16]. However, antibody
targeting in the case of molecular imaging often does not
have ideal pharmacokinetics, has a limited target-to-back-
ground ratio, and furthermore has limited capacity for
carrying magnetic resonance (MR)-detectable imaging agents
unless extensively modiﬁed. Peptides are useful as targeting
moieties with various high-throughput screening methods
being utilized to select for ideal speciﬁcity, afﬁnity, and
pharmacokinetics. To their detriment as imaging agents,
peptides generally have very short (,5 min) vascular half-lives
and a lower afﬁnity than their multivalent counterparts. The
combination of multimodal nanoparticles with targeting
peptides may circumvent some of these issues since they
can be designed as platforms with optimized pharmacoki-
netics, allow multivalent peptide attachment, are small
enough for targeting, and can be internalized into the cell
resulting in signal ampliﬁcation through intracellular trap-
ping [17].
Here, we describe the use of peptide phage display and
early passage PDAC cell lines isolated from the above mouse
models to identify peptides that distinguish both human and
murine PDAC cells from normal pancreatic ductal cells in
vitro. In addition to the generation of imaging agents, the
binding partners of the surface proteins identiﬁed in this
approach represent a snapshot of the proteome in aberrant
cells and may be useful for the delineation of the underlying
signal transduction pathways important to disease progres-
sion.
Materials and Methods
Cell Culture
Primary mouse pancreatic ductal cells from wild-type mice
were isolated and cultivated using published methods [14].
Early passage PDAC cell lines were isolated from tumors
arising in Pdx1-Cre LSL-KrasG12D p53 L/L mice (designated
Kras/p53
L/L) [11]. For the phage display experiments, PDAC
cells were ﬁrst grown in the primary duct cell media (F12
medium supplemented with 5 mg/ml D-glucose (Sigma), 0.1
mg/ml soybean trypsin inhibitor type I (Sigma), 5 ml/l insulin-
transferrin-selenium (ITSþ; BD Biosciences), 25 lg/ml bovine
pituitary extract (BD Biosciences), 20 ng/ml epidermal growth
factor (BD Biosciences), 5 nmol/l 3,39,5-triiodo-L-thyronine
(Sigma), 1 lmol/l dexamethasone (Sigma), 100 ng/ml cholera
toxin (Sigma), 10 mmol/l nicotinamide (Sigma), 5% Nu-serum
IV culture supplement (Collaborative Biomedical Products),
and antibiotics (penicillin G 100 U/ml, streptomycin 100 lg/
ml, amphotericin B 0.25 lg/ml; Gibco-BRL). Human PDAC
cell lines (MNA, 8988, SW1990, MIA-PaCa-2, ASPC) were
purchased from ATCC and cultured according to established
protocols. NIH-3T3 cells (mouse ﬁbroblasts) are purchased
from ATCC. Murine heart endothelial cells (MHEC) were
isolated from mice according to previously published proto-
cols [18] and used after the second subculture. Human
umbilical vein endothelial cells (HUVECs) were purchased
from Clonetics and cultured according to the manufacturer’s
protocol.
Mouse Cohorts
Imaging studies were performed in Pdx1-Cre LSL-
KrasG12D p53 L/þ (Kras/p53
L/þ), Pdx1-Cre LSL-KrasG12D
p16þ/  (Kras/p16
þ/ ), Pdx1-Cre LSL-KrasG12D (Kras), and
wild-type mice [11]. Breeding, genotyping, and analysis were
performed as previously published [11,12]. All mice were
housed in a pathogen-free environment at the Massachusetts
General Hospital (MGH). The mice were handled in strict
accord with good animal practice as deﬁned by the Ofﬁce of
Laboratory Animal Welfare, and all animal work was done
with Institutional Animal Care and Use Committee approval.
Phage Selection
Phage-positive selection and negative selection were
achieved by incubating mouse PDAC cells isolated from the
Kras/p53 mouse with phage (1310
11 PFU), which displayed a
randomized linear 7–amino acid peptide library (phD7, New
England Biolabs) for 1 h at 37 8C to allow time for phage to be
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izing phage affords a signal ampliﬁcation by concentrating
the imaging agent inside the cell, and in addition, the agent is
not subject to koff (off rate), further increasing the effective
afﬁnity [17]. To remove unbound phage and nonspeciﬁc
binding phage, the cells were ﬁrst washed with DPBS
supplemented with 1% BSA and 0.05% Tween-20. Cell
surface–bound phage were removed by washing with 0.1 M
glycine (pH 2) for 8 min. Following a second glycine wash, the
internalized phage were recovered by lysing the cells with
0.1% triethanolamine (Sigma) in PBS (pH 7.6) for 5 min at
RT. The internalized phage pool was neutralized with 100 ll
of 0.5 M Tris-HCl (pH 7). The counterselection was done by
incubating the internalized phage pool with normal pancre-
atic cells for three 30-min cycles to effectively subtract all
clones that bind to both normal pancreatic ductal cells and
PDAC [19]. The internalized phage were ampliﬁed in
Escherichia coli, titered, and subjected to three additional
rounds for a total of four rounds of positive selection on the
PDAC cells. From this selection, 30 clones were selected for
sequencing and analyzed by ELISA (see below).
ELISA and Multidimensional Analysis
To facilitate choosing appropriate clones, we used ELISA
and multidimensional analysis [20]. Brieﬂy, PDAC and normal
cells were grown to 100% conﬂuence in a 96-well plate and
incubated sequentially at 37 8C with the 30 phage clones (10
7
PFU, 1 h) in triplicate, washed with PBS containing 0.1%
Tween-20, incubated with biotinylated anti-M13 antibody
(1:40, 1 h), detected with streptavidin-HRP (1:500), developed
with tetra-methyl-benzidine, and absorbance650 was deter-
mined (Emax, Molecular Devices). Raw plate-reader outputs
corresponding to PDAC or normal ductal cells were
unpivoted to afford a denormalized table of values, and each
well position was then associated with similar arrays of
metadata labels. Values from each well were background
subtracted using the median value of mock-treatment wells
(wild-type phage) from each assay plate. Background-sub-
tracted (Bsub) values for mock-treatment wells were accumu-
lated across multiple assay plates to afford two mock-
treatment distributions reﬂecting assay noise, one corre-
sponding to PDAC cells and one corresponding to normal
ductal cells, and trimmed according to Chauvenet’s criterion
as previously described (17). These mock-treatment distribu-
tions were used to normalize independently each value
corresponding to a phage-treated well, affording Z-normal-
ized (Znorm) values for each well. All data formatting,
manipulation, and normalization were implemented using
Pipeline Pilot (Scitegic) and data visualizations (heat map)
were prepared using DecisionSite (Spotﬁre).
Phage Labeling
For in vitro and in vivo validation experiments, phage were
ﬂuorochrome-labeled as previously described [21]. Brieﬂy, ;1
3 10
12 PFU of phage was suspended in 100 ll of 0.3 M
NaHCO3 (pH 8.6) containing either 1 mg/ml of ﬂuorochrome-
hydrosuccinimide ester (Cy5.5 or AF750) or 0.25 mg/ml of
FITC (ﬂuorescein isothiocyanate) or RITC (rhodamine
isothiocyanate). The labeling reaction was allowed to con-
tinue in the dark at RT with gentle agitation. After 1 h, the
reaction mixture was diluted to 1 ml in DPBS, and the labeled
phage was puriﬁed by PEG precipitation (three times). The
ﬂuorochrome-labeled phage was resuspended in 200 ll DPBS.
Plaque-forming units were determined by titer analysis, and
the concentration of the ﬂuorochrome was determined
spectrophotometrically (Varian Cary 11, Varian).
Phage Detection by Fluorescent Microscopy and Flow
Cytometry
Mouse PDAC cells, human PDAC cells (MNA, 8988,
SW1990, PaCa-2, ASPC), and normal human ductal cells were
incubated with 1 lM (FITC) FITC-labeled phage clone 27 or
unrelated phage clone (amino acid sequence SNLHPSD,
negative control) for 1 h at 37 8C, washed three times with
DPBS, then harvested by incubation with trypsin, centrifuged,
and analyzed (10,000 cells/sample) by ﬂow cytometry on a
Beckton Dickinson FACSCalibur. All samples had a single
narrow peak (e.g., Figure 1B). Mean ﬂuorescence was plotted
to describe relative uptake.
Ex Vivo Biopsy Specimens
For binding of PDAC-speciﬁc peptides to ex vivo mouse
and human tissue sections (n¼3), biopsy specimens were snap
frozen, embedded in OCT, cut into 5 lm sections, and then
arrayed on slides. Slides were incubated with 1 lM of FITC-
labeled phage clone 27 or FITC-labeled control phage (no
insert) for 1 h at 37 8C, washed three times with PBS, ﬁxed
with 2% paraformaldehyde, and then visualized by ﬂuores-
cence microscopy (Nikon Eclipse TE2000-S, Insight QE, 403
objective). Informed consent was not required for use of the
human tissue specimens, as an exemption 4 applied (they
were collected as part of routine patient clinical care). No
identifying information was kept about the patients
Identification of Peptide Binding Partner
The phage were labeled with a photolinker (sulfo-SAED
[sulfosuccinimidyl 2-(7-amino-4-methylcoumarin-3-acetami-
do) ethyl-1,3 dithiopropionate]; Pierce) and biotin tag using
the same NHS chemistry used to conjugate ﬂuorochromes to
phage [21]. Two petri dishes (10 cm, Fisher Scientiﬁc) were
plated with the target cell line and grown to conﬂuency. One
plate was incubated with 1 ml of the modiﬁed phage (roughly
10
10 PFU/ll). As a negative control, the second plate was
incubated with control (no insert) phage. Both plates were
incubated in the dark at 4 8C for 1 h. The cells were then
again washed several times with DPBS, placed on ice, and
photolyzed 30 min using a 15-W 365-nm UV lamp (Spectro-
line), and lysed using 1% Triton X-100 in PBS with
mammalian protease inhibitor cocktail added (Sigma). The
cell lysates were incubated 1 h with 100 llo fD y n a l
Strepavidin beads (Invitrogen), which were preblocked with
5% BSA in PBS. The beads were washed twice with 1% Triton
X-100 in 103 PBS, then incubated overnight at 4 8C with a
buffer containing DTT to reverse the chemical crosslink and
release the precipitated protein. Half of the eluate was
transferred to a polyvinylidene ﬂuoride (PVDF) membrane
and probed with plectin-1 antibody (Santa Cruz Biotechnol-
ogy). The other half of the eluate was loaded onto a SDS-
PAGE gel (Biorad Criterion system) and stained using a mass
spectroscopy–compatible silver stain (Invitrogen).
The band was then excised and sent for tryptic digest/mass
spec analysis (Tufts Peptide Core Facility). Nanobore electro-
spray columns were constructed from 360-mm o.d., 75-mm
i.d. fused silica capillary with the column tip tapered to a 15-
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beads (Michrom BioResources), a reverse-phase packing
material, to a length of 10 cm. The ﬂow through the column
was split precolumn to achieve a ﬂow rate of 350 nl/min. The
mobile phase used for gradient elution consisted of (a) 0.3%
acetic acid 99.7% water and (b) 0.3% acetic acid 99.7%
acetonitrile. Tandem mass spectra (MS/MS) were acquired on
a Thermo LTQ ion trap mass spectrometer (Thermo). Needle
voltage was set at 3 kV. Ion signals above a predetermined
threshold automatically triggered the instrument to switch
from MS to MS/MS mode for generating fragmentation
spectra. The MS/MS spectra were searched against the NCBI
nonredundant protein sequence database using the SE-
QUEST computer algorithm [9].
Verification of Panc 27 Binding to Plectin-1
Subcellular fractionation. PDAC, PaCa-2, 293T, HUVECs,
and the normal ductal cells (mouse and human) were cultured
overnight in two wells of a six-well plate. The cells were
harvested via scraping with 500 ll of CLB (10 mM HEPES, 10
mM NaCl, 1 mM KH2PO4, 5 mM NaHCO3, 1 mM CaCl2, 0.5
mM MgCl2) supplemented with 5 mM EDTA, 10 lg/ml
aprotinin, 10 lg/ml leupeptin, and 1 lg/ml pepstatin. The
harvested cells were allowed to swell for 5 min, homogenized
50 times then centrifuged at 7,500 rpm for 5 min. The pellet
was suspended in 1 ml of TSE, 0.1% NP40, PI and
homogenized for 30 min followed with centrifugation at
5,000 rpm for 5 min. The pellet was washed twice and
suspended in 50 ll of TSE, 0.1% NP40, PI, leaving pure
nuclei. The supernatant containing the cytosol with plasma
membrane was centrifuged in a SW70 rotor at 70,000 rpm for
1 h. The pellet was resuspended and washed twice with CLB
to remove contaminating cytoplasmic proteins. Protein
concentration of each fraction was determined via BCA assay
(PIERCE Biotechnology), and equal amounts of protein from
each fraction were size-fractionated by SDS-PAGE. All
fractions were analyzed for plectin-1 expression via Western
blotting.
Competition experiments. Mouse PDAC cells were incu-
bated with FITC-labeled phage clone 27 and either anti-
plectin-1 antibody or vehicle for 1 h at 37 8C, washed,
detached, then analyzed via ﬂow cytometry (Becton Dick-
inson FACsCalibur).
Targeted nanoparticle synthesis. Plectin-1 targeted peptide
(PTP) (amino acid sequence: KTLLPTP) or control peptide
were synthesized by Tufts Peptide Core Facility with a
GGSK(FITC)C linker for conjugation of the peptide to a
model ﬂuorescent nanoparticle (crosslinked iron oxides
[CLIO]-Cy5.5). CLIO-Cy5.5 was synthesized in bulk using
established procedures [22–25], and aliquots used for the
synthesis of the various nanoparticle conjugates. Brieﬂy, T-10
dextran was dissolved in water mixed with ferric chloride and
degassed by nitrogen purging. Ferric chloride solution was
added to the mixture and the pH brought to 10 with
Figure 1. Isolation and Validation of PDAC-Specific Peptides
(A) After selection and subtraction, 30 individual phage clones were picked, amplified, and analyzed for affinity and specificity via ELISA. The heat map
depicts affinity (mean absorbance values of indicated clones in ELISA assay) and specificity (ratio of clones’ affinity to tumor cells versus normal ductal
cells). Data are displayed in terms of higher rankings (green) to lower rankings (red).
(B) FITC-labeled clone 27 binds specifically to mouse PDAC cells. FITC-27 was incubated with PDAC or normal mouse ductal cells then analyzed via
FACS.
(C) FITC-27 or FITC unrelated phage clone (negative control) were incubated with the indicated cells then analyzed via FACS. Data plotted are the mean
fluorescence units obtained from FACS analysis.
doi:10.1371/journal.pmed.0050085.g001
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linked with epichlorohydrin and ammonia to provide
stability and amine groups for conjugation of ﬂuorochromes
and peptides. NHS-Cy5.5 was reacted with amino-CLIO in
PBS overnight at 4 8C and puriﬁed by size exclusion
chromatography. Determination of Cy5.5 loading onto CLIO
was done by absorbance spectroscopy at 680 nm using
unreacted CLIO as a reference (Figure S1A). CLIO-Cy5.5
had the following physical properties: (a) size 38.7 nm (Figure
S1B), (b) relaxation time constants R1–21.1 and R2–62.6 mM/
s, and (c) an average of 2.3 Cy5.5 per CLIO nanoparticle. To
produce plectin-1 targeted or control nanoparticles, succini-
midyl iodoacetic acid was reacted with CLIO-Cy5.5 for 15
min, puriﬁed by size exclusion chromatography, then reacted
with peptidyl-cysteine for 1 h. Peptide-conjugated nano-
particles (PTP-NP) or controls (control-NP) were puriﬁed
again using size exclusion chromatography and the ratio of
peptides to nanoparticles was quantiﬁed at 497 nm by
absorbance spectroscopy using unreacted CLIO as a refer-
ence (Figure S1C).
Intravital Laser Scanning Microscopy
The laser scanning microscope with far-red and near-
infrared imaging capabilities (IV 100, Olympus) has been
described in detail elsewhere [26]. During all imaging sessions,
mice were anesthetized (2% isoﬂurane in 2 l/min O2), and a
small midline incision performed to expose the pancreas. As
an in vivo screening approach, we have used phage as
targeted nanoparticles for imaging by labeling the phage coat
proteins with a near infrared ﬂuorochrome [21,27]. The
Cy5.5-labeled phage were injected IV 4 h prior to imaging for
both the distribution and tumor imaging studies. SYTOX
green was injected 10 min prior to imaging. Subsequent to
imaging, tumors were removed for histological analysis. Serial
frozen sections were hematoxylin–eosin (HE) stained and
stained for the presence of M13 phage. For PTP-NP imaging,
the agent was injected 24 h prior to IV 100 imaging.
Angiosense (Visen Medical) was injected 10 min prior to
imaging to visualize microvasculature. Images were acquired
using appropriate triple excitation (561 nm for RITC, 633 nm
for Cy5.5, and 748 nm for Angiosense-750). After ﬂuores-
cence imaging, the pancreas was removed and embedded in
degassed 1% low melting point agar in PBS to prevent
susceptibility interfaces during subsequent MRI imaging.
Biodistribution
Mice were maintained on a nonﬂuorescent diet (Harlen-
Teklad) for 3 d prior to imaging and received an intravenous
injection of PTP-NP or control probe (15 mg Fe/kg body
weight), coupled to Cy5.5 for ﬂuorescent imaging, 24 h before
biodistribution studies were carried out. Excised tissues were
rinsed in PBS and imaged on the Siemens Bonsai system and
Olympus OV100 system using Cy5.5 ﬁlters. Probe accumu-
lation in tissues was compared to free probe, and biodis-
tribution data are expressed as a percentage of injected dose.
Fluorescence differences between the tissues were corrected
by imaging tissues/organs from animals with no probe injected
then subtracting this background from the total signal.
MRI
Pancreata imaged optically in vivo were then embedded,
and ex vivo MRI studies performed to directly correlate
intrapancreatic signal intensity changes with histology.
Imaging of resected and agar-embedded specimen was
performed using a Bruker 4.7T Pharmascan magnet, with a
38-mm diameter transmit-receive radiofrequency coil. Scout
and localizer images were obtained, followed by high-
resolution fast spin echo (FSE) and gradient echo sequences
(GE). Speciﬁcally, for the T2 weighted FSE sequence, the
following parameters were used: FOV 4.94 3 5.46 cm, matrix
size of 5123512, slice thickness of 0.5 mm, RARE factor of 8,
TE (effective) of 40 ms, TR 2811 ms, NEX of 50 for a total
acquisition time of 2 h 29 min. For the T2* weighted GE
sequence, the parameters were: FOV 333 cm, matrix size 512
3 512, slice thickness of 0.5 mm, TE of 6.8 ms, TR of 398 ms,
ﬂip angle of 30 degrees, NEX of 50, for a total acquisition
time of 2 h 49 min. Fiducial markers were included to
subsequently coregister high-resolution MRI datasets with
histologic sections.
Histology and Immunohistochemistry
Pancreas and PDAC specimens were isolated and either
ﬁxed in 10% paraformaldehyde or frozen in OCT as
previously described [11]. The histology and immunohisto-
chemical analyses were done as previously described [11].
Serial frozen sections were stained with HE or for the
presence of M13 (Amersham Biosciences) or plectin-1. Digital
images were taken using a Nikon Eclipse E400 upright
microscope (43 objective) equipped with an Insight color
camera. Serial frozen sections were stained with HE or
imaged via ﬂuorescence microscopy for the presence of PTP-
NP-Cy5.5 using a Nikon Eclipse 80i inverted microscope (203
objective) equipped with a 512 Photometrics Cascade CCD
camera (Nikon).
Results
In Vitro Selection and Validation of PDAC-Specific
Peptides
In this study, we made use of a genetically engineered
mouse model of PDAC that closely recapitulates the
histopathological, genomic, and molecular features of the
human disease [11]. The Kras/p53
L/L model [11] and wild-type
controls served as a source of early passage PDAC cell lines
and normal pancreatic ductal cells, respectively, for use in
phage display selection and subtraction procedures to
identify a pool of phage peptides speciﬁc for PDAC cells.
Subsequent to selection procedures, we isolated 30 individual
phage plaques and performed an ELISA to identify the most
selective phage for PDAC cells. The results of two experi-
ments performed in triplicate are presented in the heat map
shown in Figure 1A and in the bar graph shown in Figure S2.
The heat map depicts afﬁnity and speciﬁcity. Of the 30 phage
clones analyzed, 16 phage clones (53%) had speciﬁcity for
PDAC cells. We sequenced the top seven clones on the basis
of ELISA and multidimensional analysis. Clones 27 and 5
share identical peptide sequences (KTLLPTP) and demon-
strated ideal afﬁnity and speciﬁcity for the target PDAC cells
[17,21]. To validate clone 27 (Figure 1B) in addition to clones
1 (SGVEFLH), 9 (SKKDTHH), 15 (TMAPSIK), 17
(TQHQVTA), and 22 (VNDRNVK) (unpublished data), we
ﬂuorescein labeled the phage coat proteins and quantiﬁed
the extent of phage clone binding and speciﬁcity for mouse
PDAC and normal ductal cells via ﬂow cytometry. Clone 27
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speciﬁcity over normal ductal cells (Figure 1B). Phage clone
15 was second in afﬁnity with the rest having nearly identical
speciﬁcity (unpublished data). Together, these data demon-
strate the effectiveness of our model-based phage screens for
the identiﬁcation and validation of phage clones with high
afﬁnity and speciﬁcity for mouse PDAC.
Specificity of Peptides for Human PDAC
We further validated the speciﬁcity of clone 27 by
incubating FITC-27 or FITC-unrelated phage clone (negative
control) with mouse PDAC cells, with ﬁve human PDAC cell
lines, and with normal human ductal cells and then analyzing
uptake via ﬂuorescence-activated cell sorter (FACS). Clone 27
had an average speciﬁcity for PDAC cell lines of 141 (ratio of
clone 27/unrelated clone mean ﬂuorescence) when compared
with unrelated phage. In addition, the two phage clones had
nearly identical, weak binding to normal human ductal cells
(speciﬁcity ¼ 0.85).
We next determined the utility of the identiﬁed phage for
the detection of mouse and human PDAC. Phage clone 27
labeled with ﬂuorochrome was used as a probe to test binding
to frozen sections of normal pancreas, pancreata containing
focal PanINs, and pancreata with PDAC. While no binding
was observed in wild-type mouse pancreata or in normal
regions adjacent to lesions, prominent binding was observed
in PanINs and PDAC lesions. Control phage failed to detect
any lesions (Figure 2, bottom row). Phage clone 27, however,
was able to speciﬁcally detect human PDAC, whereas control
phage failed to stain human PDAC specimens (Figure 2, (far
right)). These results demonstrate that the phage probes bind
to evolving mouse and human PDAC, supporting the utility of
our models-based screening approach for the generation of
candidate PDAC-speciﬁc diagnostic agents.
Tumor Localization of PDAC-Targeted Phage
Since phage clones 27 and 15 had the most favorable
binding characteristics in vitro, wild-type animals or animals
harboring PanINs or palpable pancreatic tumors were
subsequently injected via tail vein with 1 nM of ﬂuorescently
labeled phage clone 27 and phage clone 15—alone or in
combination—and then imaged via intravital confocal micro-
scopy 4 h postinjection (Figure S3A). As a further control,
tumor-bearing animals were injected with labeled phage
containing a peptide isolated from an unrelated phage
display screen (Figure S3B). Clone 27 illuminated PanINs
and PDAC with a strong ﬂuorescent signal, suggesting phage
binding to tumors cells, whereas only a weak scattered signal
was observed in the pancreas of wild-type mice (Figures 3A,
3B, and S3C). The ﬂuorescent signal was virtually absent when
control phage was injected into animals harboring emerging
or advanced PDAC (Figure S3B). While clone 15 did localize
to the pancreas, total signal was less than that of clone 27,
prompting us to focus our efforts on clone 27. Clones 15 and
27 have distinctly different distributions within the pancreas
and also different peptide sequences (Figure S3A), suggesting
they target unique proteins. To further document the
speciﬁcity of phage binding in vivo, pancreata from clone
27-injected animals were ﬁxed and analyzed by immunohis-
tochemistry using antibodies speciﬁc to phage coat proteins
(Figure 3). In areas with PanINs or PDAC (black boxes in
Figure 3B and 3C), there was strong uptake of phage whereas
in regions of ductal metaplasia or normal pancreas (red boxes
in Figure 3B and 3C) phage were undetectable. These studies
Figure 2. Clone 27 Detects Human PDAC
FITC-labeled clone 27 (PDAC-27) (middle row) or wild-type phage (no peptide insert; bottom row) were incubated with frozen sections of the indicated
tissue. H&E staining of the same tissues is shown in the top row. Results shown are representative images.
doi:10.1371/journal.pmed.0050085.g002
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PDAC but was absent in normal pancreatic tissues or regions
of ductal metaplasia, which are low-grade neoplasms or
reactive lesions associated with pancreatic damage (Figure 3)
[28].
Identification of Plectin-1 as the Binding Partner for
Peptide 27
Since clone 27 showed exquisite speciﬁcity for human and
mouse PDAC in vitro and in vivo, we sought to determine its
binding partner. Using the phage as an afﬁnity ligand, a
unique 500-kDa band was identiﬁed in the mouse PDAC cell
lysates via pull-down assay (Figure 4A, left). In addition, far-
Western analysis of PDAC lysates with biotinylated phage as
the probe identiﬁed a band of similar molecular weight that
was not recognized by control phage (Figure 4A, right). Mass
spectroscopic analysis of the isolated band revealed plectin-1,
an intermediate ﬁlament and important crosslinking element
of the cytoskeleton (Figure 4B) [29]. Western blot using
lysates from the phage pulldown conﬁrmed the presence of a
band that cross-reacts with the plectin-1 antibody (Figure
4C). Plectin-1 is present in the membrane as well as the
cytoplasm of both murine and human PDAC cells (Figure
4D). Normal mouse pancreatic ductal cells had low levels of
plectin-1 expression, whereas normal human pancreatic
ductal cells had plectin-1 expression in the cytoplasm and
nucleus but not on the membrane (Figure 4D). HUVECs had
very low levels of plectin-1 expression in the nucleus. As a
control for plectin-1 expression, we used NIH-3T3 cells,
which are known to have plectin-1 in the cytoplasm and
nucleus but not on the cell surface [29]. As was expected,
plectin-1 was absent from the membrane but present in the
cytoplasmic and nuclear fractions of ﬁbroblasts (Figure 4D).
Immunohistochemical analysis of sections from normal,
PanIN, or PDAC-harboring mice corroborated the Western
analysis ﬁndings. Normal animals had scattered plectin-1
staining, whereas in PanINs and PDAC, plectin-1 was
expressed in the lesions but not in the surrounding tissue
(Figure 4E). The plectin-1 staining patterns were nearly
identical to that observed by PDAC-targeted phage shown in
Figure 3 (Figure 4E). Finally, in a competition experiment,
coincubation of anti-plectin-1 antibody and FITC-labeled
Figure 3. In Vivo Validation of Clone-27
(A) Wild type, (B) 29-wk-old Kras/p16
þ/ , and (C) 12-wk-old Kras/p53
L/þ mice were injected with Cy5.5-labeled phage clone 27 (PDAC-27) and SYTOX
green (nonspecific cell-labeling agent) then imaged via intravital confocal microscopy. Correlative Histology: Pancreata from intravital imaging
experiments were embedded in OCT, frozen, and stained with HE or anti-M13 antibody. Black boxes correspond to regions of PanIN (B) or PDAC (C) and
are magnified in the anti-M13 photomicrograph. Red boxes correspond to uninvolved adjacent regions (HE and inset in anti-M13 photomicrograph).
doi:10.1371/journal.pmed.0050085.g003
PLoS Medicine | www.plosmedicine.org April 2008 | Volume 5 | Issue 4 | e85 0663
Molecular Imaging of PDACphage clone 27 with PDAC cells resulted in 96.9% abrogation
of binding (Figure 4F).
Development of Plectin-1 Targeted PDAC Imaging Agents
In order to develop a nonbiologic, synthetic imaging agent
with translational potential, we chemically synthesized and
attached PTP to a magnetoﬂuorescent nanoparticle (PTP-NP)
(schematic, Figure 5A). The resultant MRI/optically detectable
agent was tested in 9-wk-old Kras/p53
L/þ mice. At that age,
these mice do not exhibit outward signs of illness but typically
harbor small, focal PDAC, as well as regions of normal
pancreas, ductal metaplasia, and ﬁbrosis. Twenty-four hours
after IV administration of the targeted nanoparticle, intra-
vital confocal microscopy detected discrete areas of ﬂuo-
rescence in the abdominal region of these mice, suggestive of
agent uptake (Figure 5B, left). The agent was speciﬁcally
present in the tumor tissue as a vasculature agent adminis-
tered 10 min before injection failed to colocalize (Figure 5B,
right). The in vivo ﬂuorescence correlated with surface
reﬂectance imaging of the excised pancreas where discrete
foci of signal were found (Figure 5C). In contrast, control-NP
failed to highlight any regions of the pancreas (Figure 5B,
left), although these tumors were similarly vascularized
(Figure 5B, right). Biodistribution studies revealed speciﬁc
uptake in tumors with minimal uptake in muscle or skin, two
tissues with reported plectin-1 expression (Figure 5D). In
addition, tumor uptake relative to normal pancreas was 10.1-
fold higher. Similarly, MRI showed a reduction in magnetic
resonance (MR) signal indicative of agent presence in focal
regions of the pancreas (Figure 6A). From the biodistribution
data, 3.13%-injected dose of material was present in the
tumors. Using previously established thresholds for direct
MRI sensitivity of 10 ng of Fe/g of tissue [30], we calculate that
the results are 20-fold over the threshold of detection. In
addition, it is likely that today’s sensitivity is higher than what
was previously published given available motion correction
and multi-echo chemical sequences. Histological analysis
conﬁrmed that the loss of signal associated with PTP-NP
uptake was primarily in regions of PDAC but not in normal
regions or regions of ductal metaplasia (Figure 6B). Fluo-
Figure 4. Identification and Validation of Plectin-1 Binding to Clone-27
Mouse PDAC cells were incubated with either sulfo-SAED and biotin-modified phage clone-27 or control phage, exposed to light, and lysates were
incubated with streptavidin-coated beads.
(A) Precipitated protein was eluted with dithiothreitol (DTT) then run on an SDS-PAGE gel and silver stained (left). Far Western (right): PDAC lysates were
loaded onto an SDS-PAGE gel then transferred and analyzed with clone-27 or control (no insert) biotinylated phage.
(B) A band corresponding to clone-27 affinity-purified protein from (A) was cut from the gel, digested with trypsin, and analyzed via mass spectroscopy.
(C) Affinity-purified protein from (A) was run on a SDS-PAGE gel, transferred to PVDF, and analyzed for the presence of plectin-1 with antibody to
plectin-1.
(D) 293T cells, human umbilical vein endothelial cells (HUVECs), mouse PDAC cells, mouse normal duct cells, Paca-2 cells (human PDAC), and normal
human duct cells were subcellularly fractionated, and the components probed for the presence of plectin-1.
(E) Pancreata from wild-type (left), 29-wk old Kras/p16
þ/ (center), and 12-wk old Kras/p53 (right) mice were embedded in OCT, frozen, and stained with
anti-plectin-1 antibody.
(F) Competition experiment: mouse PDAC cells were incubated with FITC-labeled clone 27 and either plectin-1 antibody or vehicle then analyzed via
FACS for the ability of clone 27 to bind.
doi:10.1371/journal.pmed.0050085.g004
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accumulation in areas of PDAC (Figure 6C, left) but not in
areas of normal pancreas (Figure 6C, right).
Discussion
Using a phage display screen and exploiting the exper-
imental merits of a reﬁned genetically engineered mouse
model of PDAC, we successfully generated a multimodal
nanoparticle-based targeted imaging agent, PTP-NP, that
allows imaging of PDAC in the background of normal,
mucinous, and ductal metaplasia of the pancreas. The
imaging agent has potential use for both MRI and endoscopy
in high-risk patients. Important issues in the development of
improved diagnostics for PDAC include the need to
distinguish pancreatic neoplasia from regions of pancreatic
damage and the need for methods that identify earlier stages
of tumor progression [31]. The imaging probes identiﬁed in
this study home to the neoplasm while showing no appreci-
able colocalization with adjacent areas or acinar-ductal
metaplasia. This speciﬁcity could be used to possibly reduce
‘‘false-positives’’ in diagnostic tests. Further, these new
imaging probes bind to PanINs as well as to advanced
cancers. The capacity to detect such premalignant lesions
could enable the development of new approaches in the
management of this disease. Although liver and kidney
uptake is high, the tomographic imaging techniques that
would be used with this probe (i.e., MRI, single photon
emission computed tomography [SPECT]/CT, or optical)
would allow the resolution of the pancreas in the context of
both organs.
In addition to the development of novel molecularly
targeted imaging agents, phage display screening and
modiﬁed immunoprecipitation permitted the identiﬁcation
of membrane-localized plectin-1 as a potential new bio-
marker for PDAC. Differential protein processing and/or
trafﬁcking, identiﬁed using proteomic approaches, repre-
sents a potential class of biomarkers that would be missed if
looking at cDNA expression data only or using whole-cell
proteomics methods. For example, the binding partner of
clone 15 identiﬁed from this screen represents an additional
biomarker that may shed light on aberrant molecular
pathways contributing to PDAC pathogenesis.
Plectin-1 is a high molecular weight protein (500 kDa) that
links intermediate ﬁlaments to microtubules and microﬁla-
ments and also anchors the cytoskeleton, the plasma, and
nuclear membranes (reviewed in [29]). We have shown that
plectin-1 levels are low in normal pancreatic ductal cells, but
Figure 5. Fluorescence Imaging of PDAC Using PTP-NP or Control-NP
(A) Schematic of conjugation of PTP to NP. Control-NP is synthesized the same way with substitution of control peptide for PTP.
(B) Intravital confocal microscopy of early pancreatic lesions imaged using PTP-NP (red, top) or control-NP (red, bottom) and AF750-labeled bloodpool
agent (blue).
(C) Low-magnification view of pancreatic fluorescence shows distribution of PTP-NP in distinct areas of the pancreas. White light overlay provides
anatomic correlation (left). Dotted line outlines the pancreas.
(D) Biodistribution of PTP-NP and control-NP.
doi:10.1371/journal.pmed.0050085.g005
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Molecular Imaging of PDACits expression is upregulated in PanINs and remains elevated
in PDAC. Perhaps more importantly, plectin-1 exhibits
distinct cytoplasmic and nuclear localization in normal
ﬁbroblasts, whereas an aberrant expression on the cell
membrane is observed in PDAC. Studying the mechanisms
of protein upregulation, differential trafﬁcking, and whether
plectin-1 contributes to disease progression are important
future experiments. Notable in this regard, recent publica-
tions illustrate that plectin-1 can be recruited to the
membrane during epithelial cell transformation [32]. Altered
subcellular localization of plectin-1 is also observed in the
autoimmune condition, paraneoplastic pemphigus, and in
the associated lymphoproliferative neoplasm, Castleman
disease [33]. Plectin-1 has a number of important roles in
signal transduction, inﬂuencing Rho activity [34], and serving
as a scaffold for proteins involved in protein kinase C (PKC)
[35] and AMP-activated protein kinase signaling pathways
[36]. Thus, plectin-1 in PDAC may have an impact on
signaling pathways that regulate cell migration, polarity,
and energy metabolism.
Noninvasive imaging has particular applications in high-
risk groups—hereditary PDAC kindreds and new-onset
diabetes patients—who are currently targets of screening
for pancreatic cancer. Despite the increased risk in these
individuals, the incidence of pancreatic cancer will only be
;0.4%–0.6% [37], hence surgery, which carries substantial
morbidity and mortality, is not typically carried out
prophylactically. Traditional imaging such as CT scan or
MRI often do not detect PDAC lesions until they have
reached a size at which many tumors have already metasta-
sized—rendering surgery ineffective. There is, consequently,
a considerable need for a new imaging modality that would
accurately identify the presence of PDAC at an earlier point
in its evolution—when surgery is effective. Other settings for
noninvasive imaging of incipient cancers include patients
with cystic neoplasms: intraductal papillary mucinous neo-
plasms (IPMN) and mucinous cystic neoplasms (MCN). These
tumors are often benign, however a subset progress to PDAC.
Furthermore, there may be utility for these approaches in
postsurgical screening for recurrence and screening prior to
surgery to determine exact tumor extension more accurately.
Finally, we envision that the approach could be clinically
valuable in differential diagnosis, i.e., patients presenting
with pancreatitis, jaundice, or upper abdominal pain. In
screening of high-risk groups, it will be important to be able
to distinguish low-grade PanINs, which are present in many
healthy individuals, from high-grade PanINs and carcinoma
in situ. The ideal probes would recognize lesions of PanIN-3
and higher since these are thought to have very high potential
for progressing to invasive PDAC. Further work will be
required to deﬁne whether the plectin-1 targeted nano-
particles discriminate between low-grade PanINs and high-
Figure 6. MRI and Correlative Histology
(A and B) Three adjacent slices (A) from an ex vivo MRI of the pancreas from a 9-wk-old Kras/p53
L/þmouse demonstrates focal nanoparticle uptake (one
example, yellow arrow), which corresponds to tumor seen on correlated HE sections (B), but not to regions of ductal metaplasia or normal pancreas
(labeled).
(C) Fluorescence microscopy of adjacent sections demonstrate uptake of Cy5.5-labeled PTP-NP in regions of tumor (left) but not in adjacent tissue
(right).
doi:10.1371/journal.pmed.0050085.g006
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Molecular Imaging of PDACgrade PanINs. Translational studies can be conducted in
patients undergoing resection; the rapid homing of the agent
to tumors and subsequent clearance from the body makes this
technically feasible.
Genetically engineered mouse models of human cancers
effectively recapitulate many of the molecular, biological, and
clinical features of the human disease [11,12]. Recent
genomics studies of mouse and human cancers have
established that cross-species analysis can serve as an effective
ﬁlter in identifying recurrent alterations [38,39]. Our studies
here show that the utility of such mouse models extends to
the development of molecularly targeted imaging agents. We
identiﬁed conserved markers of early disease in screens that
took advantage of mouse cell lines derived from the early
stages of cancer development and primary pancreatic ductal
cells. Furthermore, the known kinetics of tumor progression
of our mouse model facilitated testing of the imaging probes
at deﬁned stages of tumorigenesis. The approaches described
here may be broadly applicable to the discovery of cancer
biomarkers predictive of disease stage, prognosis, or presence
of speciﬁc genetic alterations.
Supporting Information
Figure S1. Characterization of Nanoparticles
(A) CLIO-Cy5.5 absorbance spectroscopy used for quantitation of
number of Cy5.5/nanoparticle.
(B) Size distribution of CLIO via light scattering.
(C) Absorbance spectroscopy of PTP-NP-Cy5.5 used to quantitate the
number of peptides/nanoparticle. Notice background absorbance
from nanoparticle below 500 nm, whose contribution is subtracted
via reference to unreacted CLIO.
Found at doi:10.1371/journal.pmed.0050085.sg001 (287 KB TIF).
Figure S2. Phage Clone Validation Via ELISA
After selection and subtraction, 30 individual phage clones were
picked, ampliﬁed, and analyzed for afﬁnity and speciﬁcity via ELISA.
Found at doi:10.1371/journal.pmed.0050085.sg002 (708 KB TIF).
Figure S3. In Vivo Imaging with Phage Clones 15 and 27
(A) Cy5.5-labeled phage clone 27 and RITC-labeled phage clone 15
were coinjected into Kras/p53
L/þ, and tumor binding analyzed via
intravital confocal microscopy.
(B) Unrelated phage clone was injected into Kras/p53
L/þ and analyzed
via intravital confocal microscopy.
(C) Cy5.5-labeled phage clone 27 was injected into a wild-type mouse
and analyzed via intravital confocal microscopy.
Found at doi:10.1371/journal.pmed.0050085.sg003 (1.4 MB TIF).
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Editors’ Summary
Background. Pancreatic cancer is a leading cause of cancer-related
death in the US. Like all cancers, it occurs when cells begin to grow
uncontrollably and to move around the body (metastasize) because of
changes (mutations) in their genes. If pancreatic cancer is found early,
surgical removal of the tumor can sometimes provide a cure.
Unfortunately, this cancer rarely causes any symptoms in its early stages
and the symptoms it does eventually cause—jaundice, abdominal and
back pain, and weight loss—are also seen in other illnesses. In addition,
even though magnetic resonance imaging (MRI) or other noninvasive
imaging techniques can be used to look at the pancreas, by the time
tumors are large enough to show up on MRI scans, they have often
already spread. Consequently, in most patients, pancreatic cancer is
advanced by the time a diagnosis is made, hence surgery is no longer
useful. These patients are given radiotherapy and chemotherapy but
these treatments are rarely curative and most patients die within a year
of diagnosis.
Why Was This Study Done? If more pancreatic cancers could be found
before they had metastasized, it should extend the life expectancy of
patients with this type of cancer. An early detection method would be
particularly useful for monitoring people at high risk of developing
pancreatic cancer. These include people with certain inherited cancer
syndromes, pancreatitis (inflammation of the pancreas), and diabetes.
Because cancer cells have many mutations, they express different
proteins on their cell surface from normal cells. If these proteins could be
identified, it might be possible to develop an ‘‘imaging probe’’—a
molecule that binds to a protein found only on cancer cells and that can
be detected with MRI, for example—for early detection of pancreatic
cancer. In this study, the researchers use a technique called ‘‘phage
display’’ to identify several peptides (short sequences of amino acids, the
constituent parts of proteins) that specifically bind to pancreatic cancer
cells early in their development. They then investigate the possibility of
developing an imaging probe from one of these peptides.
What Did the Researchers Do and Find? The researchers isolated early
pancreatic cancer cells from a mouse model of human pancreatic ductal
adenocarcinoma (PDAC; the commonest type of pancreatic cancer).
Then, by mixing together these cells and normal mouse pancreatic cells
with a library of phage clones (phages are viruses that infect bacteria; a
clone is a group of genetically identical organisms), each engineered in
the laboratory to express a random seven amino-acid peptide, they
identified one clone, clone 27, that bound to the mouse tumor cells but
not to normal cells. Clone 27 also showed up in the cancer cells in
samples of mouse pancreatic intraepithelial neoplasias (PanINs; pre-
cursors to pancreatic cancer), mouse PDACs, and human PDACs.
The peptide in clone 27, the researchers report, binds to plectin-1, a
protein present both inside and on the membrane of human and mouse
PDAC cells but only on the inside of normal pancreatic cells. Finally, the
researchers attached this plectin-1–targeted peptide (PTP) to a
nanoparticles that was both magnetic and fluorescent (PTP-NP) and
used special microscopy (which detects the fluorescent part of this very
small particle) and MRI (which detects its magnetic portion) to show that
this potential imaging probe was found in areas of PDAC (but not in
normal pancreatic tissue) in the mouse model of human PDAC.
What Do These Findings Mean? These findings identify PTP as a
peptide that can distinguish normal pancreatic cells from pancreatic
cancer cells. The discovery that plectin-1 (a cytoskeletal component) is
abnormally expressed on the cell surface of PDACs provides new
information about the development of pancreatic cancer that could
eventually lead to new ways to treat this disease. These findings also
show that PTP can be used to generate a nanoparticle-based imaging
agent that can detect PDAC within a normal pancreas. These results
need to be confirmed in people—results obtained in mouse models do
not always reflect what happens in people. Nevertheless, they suggest
that PTP-NPs might allow the noninvasive detection of early tumors in
people at high risk of developing pancreatic cancer, an advance that
could extend their lives by identifying tumors earlier, when they can be
removed surgically.
Additional Information. Please access these Web sites via the online
version of this summary at http://dx.doi.org/10.1371/journal.pmed.
0050085.
  The Panreatic Cancer Action Network and the Lustgarten Foundation
for Pancreatic Cancer Research provide information, support, and
advocacy for patients, families, and healthcare professionals
  The MedlinePlus Encyclopedia has a page on pancreatic cancer (in
English and Spanish). Links to further information are provided by
MedlinePlus
  The US National Cancer Institute has information about pancreatic
cancer for patients and health professionals (in English and Spanish)
  The UK charity Cancerbackup also provides information for patients
about pancreatic cancer
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